MyFinsight
Home
Blog
About
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$18,366,803
Free Cash flow
-$12,443,612
Unit: Dollar
Positive Cash Flow Breakdown
Maturities of investments - mark...
Stock-based compensation expense
Accrued expenses and other curre...
Prepaid expenses and other curre...
Negative Cash Flow Breakdown
Purchases of investments - marke...
Net loss
Prepaid research and development
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-19,591,231
-16,380,840
-12,734,651
-11,930,280
Depreciation
0
0
0
23,687
Stock-based compensation expense
5,346,010
5,559,766
4,533,780
4,525,206
Write-off of in-process research and development
0
0
0
0
Change in fair value
0
373,354
-642,169
492,827
Non-cash accretion on marketable securities
1,154,664
814,923
366,472
570,503
Operating lease right-of-use assets
0
0
0
34,918
Prepaid expenses and other current assets
-358,875
949,439
-275,411
-249,795
Prepaid research and development
1,831,731
-487,083
791,427
1,071,711
Other assets
88,938
60,638
37,208
57,913
Accounts payable
-625,585
429,251
537,526
-1,983,355
Operating lease liabilities
0
0
0
37,944
Accrued expenses and other current liabilities
5,143,652
43,372
424,899
718,197
Net cash used in operating activities
-12,443,612
-12,059,722
-7,515,973
-10,592,730
Purchases of equipment and improvements
0
0
0
0
Purchases of investments - marketable securities
55,033,702
90,584,587
98,847
38,996,000
Maturities of investments - marketable securities
49,125,000
10,100,000
0
10,249,897
Acquired in-process research and development
0
0
0
0
Net cash provided by (used in) investing activities
-5,908,702
-80,484,587
-98,847
-28,746,103
Deferred offering costs
399,551
-
-
-385,062
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs
0
2,897,611
107,617,345
0
Issuance of common stock from exercise of stock options
0
-
562,915
250,932
Net cash provided by financing activities
-14,489
2,897,611
108,565,322
-134,130
Net increase (decrease) in cash and cash equivalents
-18,366,803
-89,646,698
100,950,502
-39,472,963
Cash and cash equivalents at beginning of period
49,573,510
139,220,208
38,269,706
56,490,579
Cash and cash equivalents at end of period
31,206,707
49,573,510
139,220,208
38,269,706
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$18,366,803
(-186.42%↓ Y/Y)
Stock-based compensation
expense
$5,346,010
(-14.48%↓ Y/Y)
Accrued expenses and
other current...
$5,143,652
(1892.46%↑ Y/Y)
Prepaid expenses and
other current assets
-$358,875
(-4668.47%↓ Y/Y)
Maturities of investments -
marketable securities
$49,125,000
(56.70%↑ Y/Y)
something is missing
$385,062
Net cash used in
operating activities
-$12,443,612
(-28.58%↓ Y/Y)
Net cash provided by
(used in) investing...
-$5,908,702
(-119.12%↓ Y/Y)
Net cash provided by
financing activities
-$14,489
(-145.60%↓ Y/Y)
Canceled cashflow
$10,848,537
Canceled cashflow
$49,125,000
Canceled cashflow
$385,062
Net loss
-$19,591,231
(16.97%↑ Y/Y)
Purchases of investments -
marketable securities
$55,033,702
Deferred offering costs
$399,551
Prepaid research and
development
$1,831,731
(3083.02%↑ Y/Y)
Non-cash accretion on
marketable securities
$1,154,664
Accounts payable
-$625,585
(-139.28%↓ Y/Y)
Other assets
$88,938
Buy us a coffee